PHASE I TRIAL OF A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 ANTIBODY, huOKT3γ1(Ala-Ala) IN THE TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION

Autor: Woodle, E. Steve, Xu, Danlin, Zivin, Robert A., Auger, Julie, Charette, Jane, O'Laughlin, Rita, Peace, Donna, Jolliffe, Linda K., Haverty, Thomas, Bluestone, Jeffrey A., Thistlethwaite, J. Richard
Zdroj: Transplantation; September 1999, Vol. 68 Issue: 5 p608-616, 9p
Abstrakt: HuOKT3γ1(Ala-Ala) is a genetically-engineered derivative of the parental murine OKT3 monoclonal antibody, in which the six complementarity-determining regions have been grafted within a human IgG1 mAb, and whose CH2 region has been altered by site-directed mutagenesis to alter FcR-binding activity, thereby eliminating T cell activation properties. This report describes the results of a phase I trial of huOKT3γ1(Ala-Ala) treatment of acute renal allograft rejection.
Databáze: Supplemental Index